Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Albendazole
Drug ID BADD_D00052
Description A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Indications and Usage For the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
Marketing Status approved; vet_approved
ATC Code P02CA03
DrugBank ID DB00518
KEGG ID D00134
MeSH ID D015766
PubChem ID 2082
TTD Drug ID D00KVO
NDC Product Code 49452-0003; 51927-1763; 52286-0001; 63629-1221; 64896-693; 60592-002; 42799-110; 43598-452; 69539-151; 52286-5500; 42291-093; 69097-237; 69766-026; 0115-1701; 53104-7736; 31722-935; 51407-258; 63629-9278; 72205-051; 0591-2712; 51927-0068; 72643-008; 86055-0004; 73309-129; 70710-1021; 70771-1103; 78482-110
UNII F4216019LN
Synonyms Albendazole | Lurdex | Bilutac | Metiazol | Andazol | Albenza | Zentel | Albendoral | Albendazole Monohydrochloride | Monohydrochloride, Albendazole | Bendapar | Digezanol | Disthelm | Mediamix V Disthelm | Endoplus | Eskazole | Gascop | SK&F-62979 | SK&F 62979 | SK&F62979 | SKF-62979 | SKF 62979 | SKF62979 | Valbazen
Chemical Information
Molecular Formula C12H15N3O2S
CAS Registry Number 54965-21-8
SMILES CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.0030.003381%
Vision blurred17.17.01.010; 06.02.06.0070.003381%
Vomiting07.01.07.0030.012679%
Lymphatic disorder01.09.01.003--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Haematotoxicity12.03.01.025; 01.05.01.0070.001691%Not Available
Meningeal disorder17.02.10.003--Not Available
Abnormal behaviour19.01.01.0010.002536%Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.011834%
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Bone marrow failure01.03.03.0050.001691%
Low birth weight baby18.04.02.0030.001691%Not Available
Skin mass23.07.04.0140.001691%Not Available
Acute kidney injury20.01.03.0160.001691%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.009298%Not Available
Faeces pale07.01.03.0050.001691%Not Available
Normal newborn18.08.06.0010.008622%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.005410%Not Available
Gait inability17.02.05.069; 08.01.02.0110.007607%Not Available
Superficial inflammatory dermatosis23.03.04.0510.002536%Not Available
The 4th Page    First    Pre   4    Total 4 Pages